Exact Sciences Corp
XMUN:EXK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Exact Sciences Corp
XMUN:EXK
|
US |
|
Norbit ASA
OTC:NBITF
|
NO |
|
E
|
Eurazeo SE
SWB:EUQ
|
FR |
|
D
|
Deutsche Bank AG
XHAM:DBK
|
DE |
Exact Sciences Corp
Exact Sciences makes cancer screening and diagnostic tests that help doctors find cancer earlier and choose treatment. Its best-known product is Cologuard, a noninvasive stool test for colon cancer screening. It also sells tumor testing used after a cancer diagnosis, such as Oncotype DX, which helps doctors understand how aggressive a tumor is and whether certain treatments are likely to help. The company sells mainly to physicians, hospitals, health systems, and patients, with reimbursement from insurers and other payers playing a big role in how its tests are used and paid for. Exact Sciences earns money each time one of its tests is ordered and processed in its labs, so it sits between the doctor who orders the test and the patient who needs the result. That makes it part diagnostics company and part clinical testing service. What sets the business apart is that it focuses on specific cancer decisions where a lab result can change care. Instead of making a drug or a machine, it sells evidence-based tests backed by proprietary science and large-scale lab operations. Its role in healthcare is to turn patient samples into clear answers that can guide screening, diagnosis, and treatment.
Exact Sciences makes cancer screening and diagnostic tests that help doctors find cancer earlier and choose treatment. Its best-known product is Cologuard, a noninvasive stool test for colon cancer screening. It also sells tumor testing used after a cancer diagnosis, such as Oncotype DX, which helps doctors understand how aggressive a tumor is and whether certain treatments are likely to help.
The company sells mainly to physicians, hospitals, health systems, and patients, with reimbursement from insurers and other payers playing a big role in how its tests are used and paid for. Exact Sciences earns money each time one of its tests is ordered and processed in its labs, so it sits between the doctor who orders the test and the patient who needs the result. That makes it part diagnostics company and part clinical testing service.
What sets the business apart is that it focuses on specific cancer decisions where a lab result can change care. Instead of making a drug or a machine, it sells evidence-based tests backed by proprietary science and large-scale lab operations. Its role in healthcare is to turn patient samples into clear answers that can guide screening, diagnosis, and treatment.
Record Results: Exact Sciences reported its highest quarterly revenue growth in over two years, with revenue up 20% year-over-year to $851 million.
Guidance Raised: The company raised full-year 2025 revenue guidance to $3.22–$3.235 billion and adjusted EBITDA guidance to $470–$480 million.
Screening Drives Growth: Screening revenue grew 22% year-over-year to $666 million, fueled by Cologuard adoption, health system integrations, and care gap programs.
Cologuard Plus Momentum: Cologuard Plus saw expanded payer coverage and contributed 200–300 basis points to screening growth in Q3, with more impact expected in Q4.
Cancerguard Launch: Cancerguard, a multi-cancer early detection test, was launched and is expected to ramp up with direct-to-consumer marketing and provider education.
Productivity & Cash Flow: Adjusted EBITDA grew 37% year-over-year, margins expanded, and free cash flow reached $190 million for the quarter.
Care Gap Programs: Record care gap shipments boosted volumes but temporarily pressured gross margins, which are expected to rebound in Q4.
